Business
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
HOUSTON, April 01, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna.
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated "Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer’s disease"","length":217,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, April 01, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna.","length":497,"tagName":"p"},{"type":"text","content":"The presentation, titled, "A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer’s disease," will take place on April 5, 2025.","length":176,"tagName":"p"},{"type":"text","content":"About Coya Therapeutics, Inc.","length":29,"tagName":"p"},{"type":"text","content":"Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.","length":557,"tagName":"p"},{"type":"text","content":"Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.","length":293,"tagName":"p"},{"type":"text","content":"For more information about Coya, please visit www.coyatherapeutics.com","length":70,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"This press release contains "forward-looki...